---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344666"
form_type: "8-K"
ticker: "MOBI"
cik: "0001489993"
company_name: "Mobia Medical, Inc."
filed_at: "2026-08-11T20:12:00+00:00"
generated_at: "2026-08-11T20:13:06.360193+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mobia Medical Q2 revenue $13.5M (+102% YoY), net loss $21.0M; FY26 guide $54-56M

## Summary
- Revenue $13.5M vs $6.7M in Q2 2025, up 102%; gross margin 83.2% vs 82.3%.
- Net loss $21.0M ($1.10/share) vs $10.5M loss ($12.44/share) in prior year; per-share drop reflects IPO share conversion.
- Cash and equivalents $177.1M as of June 30, 2026; IPO closed May 2026 with ~$134.0M net proceeds.
- FY2026 revenue guidance $54-56M, implying 69-75% growth over 2025.
- Published two-year VNS-REHAB follow-up data in Neurology; appointed Myriam Curet, M.D. and Reza Zadno, Ph.D. to board.

## SEC filing metadata
- accession: 0001193125-26-344666
- form_type: 8-K
- ticker: MOBI
- cik: 0001489993
- company_name: Mobia Medical, Inc.
- filed_at: 2026-08-11T20:12:00+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1489993/000119312526344666/0001193125-26-344666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1489993/000119312526344666/mobi-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344666
- JSON: https://secwatch.observer/filing/0001193125-26-344666.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344666.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.